Investment is breath of fresh air

A UofG spinout which aims to create more effective methods of treating lung diseases has secured a £1 million grant from Innovate UK. The award will help advance the development of nebuliser technology which uses an innovative surface acoustic wave technique to deliver medicines into patients’ lungs. Acu-Flow’s technology, known as Nebu~Flow, provides key advantages over existing technologies by producing droplets from a wide range of formulations within the clinical proven optimum range, capable of reaching patients’ lungs and maximising the treatment’s effectiveness, so reducing the time required to deliver a dose.

Dr Elijah Nazarzadeh is Acu-Flow’s CEO and a co-founder: “Our new technology will not only improve the amount of drug reaching the lung, but will enable new drug formulations, helping pharmaceutical companies to develop the next generation of life-changing treatments.”